Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Masatoshi Eto

ResearcherPublications, citations & collaboration network

Masatoshi Eto is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 742 works, 11,103 citations, an h-index of 50 and an i10-index of 238.

742
Works
11,103
Citations
50
h-index
238
i10-index

How has Masatoshi Eto's publication output changed over time?

ScholarIQpublication output · 2009–2024

Output grew0% over the shown period — from 1 works in 2009 to 1 in 2024.

1
1
1
1
1
1
2
1
1
1
2009201120142018201920202021202220232024

What are the most-cited papers on Masatoshi Eto?

ScholarIQmost cited works
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frédéric Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri
New England Journal of Medicine. 20211,781 CitationsOPEN ACCESS
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Thomas Powles, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Howard Gurney, Yen‐Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Joseph E. Burgents, Lei Xu, Kentaro Imai, David I. Quinn, Toni K. Choueiri, Piotr Tomczak, Toni K. Choueiri, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Jaroslav Hájek, Tzu-Ping Lin, Stefan N. Symeonides, Jae‐Lyun Lee, Piotr Sawrycki, Naomi B. Haas, Howard Gurney, Mauricio Mahave, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Christine Chevreau, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Delphine Topart, Stéphane Oudard, Evgeniy Kopyltsov, H. Hammers, David I. Quinn, Ajjai Alva, Juliana de Menezes, Adriano Gonçalves e Silva, Eric Winquist, Alketa Hamzaj, Giuseppe Procopio, Boguslawa Karaszewska, Ewa M. Nowakowska-Zajdel, B. Yа. Alekseev, Rustem Gafanov, А. А. Измайлов, Andrey Semenov, S. G. Afanasyev, Oleg Lipatov, T.B. Powles, Sandy Srinivas, David F. McDermott, Samith T. Kochuparambil, Ian D. Davis, Katriina Peltola, Roberto Sabbatini, Jinsoo Chung, М. I. Shkolnik, В. Б. Матвеев, P. Gajate Borau, Steven McCune, Thomas E. Hutson, Alejandro Dri, Silvio Correia Sales, Carrie Yeung, Carmen Marcela Alcala Castro, Peter J. Boström, Brigitte Laguerre, Consuelo Buttigliero, Ugo De Giorgi, Eugeniy A. Fomin, Yousef Zakharia, Clara Hwang, Eric A. Singer, Jeffrey T. Yorio, David Waterhouse, Rubén Dario Kowalyszyn, Margarita Sonia Alfie, Eduardo Yañez Ruiz, Tomáš Büchler, Krista Kankaanranta, G. Ferretti, Go Kimura, Kazuo Nishimura, Naoya Masumori, Satoshi Tamada, Haruaki Kato, Hiroshi Kitamura, Iwona Danielewicz
The Lancet Oncology. 2022284 CitationsOPEN ACCESS
Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma
Yoshihiro Komohara, Hasita Horlad, Koji Ohnishi, Yukio Fujiwara, Shinya Suzu, Masatoshi Eto, Motohiro Takeya
S175946340. 2011269 Citations
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
Marine Gross‐Goupil, Tae‐Geon Kwon, Masatoshi Eto, Dingwei Ye, Hideaki Miyake, S.I. Seo, S.-S. Byun, Jia-Lin Lee, Viraj A. Master, Jie Jin, R. DeBenedetto, R. Linke, Michelle Casey, Brad Rosbrook, Mariajosé Lechuga, Olga Valota, Enrique Grande, David I. Quinn
Annals of Oncology. 2018260 CitationsOPEN ACCESS
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Robert J. Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, B. Yа. Alekseev, Sun Young Rha, Jaime R. Merchan, Jeffrey C. Goh, Aly‐Khan A. Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung‐Hoo Hong, Howard Gurney, María José Méndez, Evgeny Kopyltsov, Sergei Tjulandin, Teresa Alonso‐Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph E. Burgents, Cixin He, Chinyere E. Okpara, Jodi A. McKenzie, Toni K. Choueiri, for the CLEAR Trial Investigators, Robert J. Motzer, Toni K. Choueiri, Thomas E. Hutson, Luke T. Nordquist, David R. Spigel, Jaime R. Merchan, Saby George, Sandhya Srinivas, Brendan D. Curti, Andrew Pippas, Elisabeth I. Heath, Subramanya Rao, Theodore Stewart Gourdin, Mehmood Hashmi, Nafisa Burhani, Ana M. Molina, Alan J. Koletsky, Robert Alter, C. Alemany, Benjamin A. Gartrell, Mike Cusnir, Harsha Vyas, Stephanie L. Graff, Christian Squillante, Mark Knapp, Ivor Percent, Vijay Patel, Daniel L. Spitz, C. Harkness, Marc Matrana, Lindsay Overton, Stephen Richey, Donald Richards, Habib M. Ghaddar, Robert Galamaga, Ralph J. Hauke, Joseph Haggerty, Ronald Harris, Mark Johns, Samith T. Kochuparambil, Christian Kollmannsberger, Bobby Shayegan, Christina Canil, Eric Winquist, Catherine Sperlich, Georg A. Bjarnason, Naveen S. Basappa, Wolfgang Loidl, Wolfgang Horninger, Manuela Schmidinger, Lionel D’Hondt, Dirk Schrijvers, Annemie Rutten, Peter Schatteman, Wim Wynendaele, Daisy Luyten, Spyridon Sideris, Christine Gennigens, Bohuslav Melichar, Jana Katolická, Jiří Tomášek, Jana Prausová, Tomáš Büchler
Journal of Clinical Oncology. 2024170 CitationsOPEN ACCESS

Related on ScholarIQ

Kyushu University
Institution
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Paper
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Paper
Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma
Paper
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
Paper
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Paper
470M+ articles · free account